Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00179023 · ClinicalTrials.gov registry record · Phase 1
The Autonomic Nervous System and Obesity
A Phase 1 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 1
- Development phase
- 128
- Enrollment target
NCT00179023: Completed Phase 1 study, sponsored by Vanderbilt University.
NCT00179023 is a Phase 1 study that has completed, run by Vanderbilt University. The registered enrollment target is 128 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (113% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00179023, a Phase 1 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 128 participants
- Enrollment target
Study Summary
In its simplest terms, obesity is the results of a positive balance between food intake and energy expenditure (EE). I.e., we take in more energy, in the form of food, than we expend, e.g., by exercise. In our sedentary society, resting EE accounts for most of total energy expenditure. The sympathetic nervous system (SNS, the one that produces adrenaline) is thought to contribute to resting EE. This conclusion is based on experiments where resting EE is decreased by beta-blockers, high blood pressure medicines that block only one aspect of the sympathetic nervous system. The investigators propose to use a different approach, by using a medication called trimethaphan that produces transient withdrawal of the autonomic nervous system. The investigators will then compare the measured resting EE before and after SNS withdraw and quantify the degree of contribution to the resting EE by the SNS and delineate differences between healthy normal, healthy obese, and patients with autonomic dysfunctions.
Interventions
- DRUG Trimethaphan
- DRUG Pseudoephedrine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2003-04 |
| Est. Completion | 2017-01 |
| Phase | Phase 1 |
What the finished NCT00179023 record still lists
NCT00179023 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (113% higher).
The record links to 0 conditions, and to 2 interventions - of which Trimethaphan is the first listed.
NCT00179023 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00179023 about?
NCT00179023 is a clinical study titled "The Autonomic Nervous System and Obesity". In its simplest terms, obesity is the results of a positive balance between food intake and energy expenditure (EE). I.e., we take in more energy, in the form of food, than we expend, e.g., by exercise. In our sedentary society, resting EE accounts for most of total energy expenditure. The sympathet...
What is the current status of trial NCT00179023?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2003-04. Estimated completion is 2017-01.
What interventions are being tested in trial NCT00179023?
The interventions under investigation include: Trimethaphan (DRUG), Pseudoephedrine (DRUG).
Who is sponsoring clinical trial NCT00179023?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00179023's enrollment target sits among peer trials
128 452nd of 2000 higher than 1,542 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia